Michael North, an Insider in Amedisys, Inc. (AMED), Sold 11000 shares of the Company; Torm Plc – Class A (TRMD) SI Decreased By 35%

May 16, 2018 - By Winifred Garcia

Amedisys, Inc. (NASDAQ:AMED) Logo

Torm Plc – Class A (NASDAQ:TRMD) had a decrease of 35% in short interest. TRMD’s SI was 6,500 shares in May as released by FINRA. Its down 35% from 10,000 shares previously. With 2,700 avg volume, 2 days are for Torm Plc – Class A (NASDAQ:TRMD)’s short sellers to cover TRMD’s short positions. It closed at $7.93 lastly. It is down 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

TORM plc, a product tanker company, transports refined oil products worldwide. The company has market cap of $593.11 million. The firm transports refined oil products, such as gasoline, jet fuel, naphtha, and diesel oil. It has a 203.33 P/E ratio. As of March 8, 2018, it had a fleet of 80 vessels.

Mr. Michael North, the important Chief Information Officer at Amedisys Inc has lately been linked with an open market transaction of 11,000 shares of the ‘s company, valued at $71.5 per share. The transaction amounted to a total value of of $786,708 U.S Dollars. Dated 14-05-2018, this shares transaction by Michael North was unveiled in a filing filed with the D.C. based-SEC. It is ready for use here. The regulatory filing shows that Michael North now owns around 0.07% of the Louisiana-based company’s market capitalization

More notable recent Amedisys, Inc. (NASDAQ:AMED) news were published by: Nasdaq.com which released: “Amedisys to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference” on May 14, 2018, also Seekingalpha.com with their article: “Amedisys’ (AMED) CEO Paul Kusserow on Q1 2018 Results – Earnings Call Transcript” published on May 13, 2018, Globenewswire.com published: “Amedisys Celebrates More Than 5700 Nurses During National Nurses Week” on May 07, 2018. More interesting news about Amedisys, Inc. (NASDAQ:AMED) were released by: Globenewswire.com and their article: “Amedisys Welcomes Sharon Brunecz as Chief Human Resources Officer” published on April 24, 2018 as well as Globenewswire.com‘s news article titled: “Amedisys Announces First Quarter Earnings Release and Conference Call Date” with publication date: April 30, 2018.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $2.50 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 83.34 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Among 15 analysts covering Amedisys Inc. (NASDAQ:AMED), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Amedisys Inc. has $8000 highest and $39 lowest target. $62.27’s average target is -15.09% below currents $73.34 stock price. Amedisys Inc. had 43 analyst reports since September 1, 2015 according to SRatingsIntel. Robert W. Baird maintained Amedisys, Inc. (NASDAQ:AMED) rating on Wednesday, January 13. Robert W. Baird has “Neutral” rating and $39 target. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Buy” rating by Benchmark on Thursday, November 2. The rating was maintained by Mizuho with “Neutral” on Wednesday, March 1. Robert W. Baird maintained Amedisys, Inc. (NASDAQ:AMED) on Sunday, November 5 with “Hold” rating. On Wednesday, July 19 the stock rating was maintained by Jefferies with “Buy”. The stock of Amedisys, Inc. (NASDAQ:AMED) has “Buy” rating given on Monday, November 7 by Mizuho. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Neutral” rating by Robert W. Baird on Friday, November 10. As per Thursday, March 10, the company rating was maintained by Oppenheimer. The firm has “Hold” rating given on Sunday, October 22 by RBC Capital Markets. The rating was maintained by Jefferies on Tuesday, September 5 with “Buy”.

Investors sentiment increased to 1.77 in 2017 Q4. Its up 0.06, from 1.71 in 2017Q3. It increased, as 12 investors sold Amedisys, Inc. shares while 44 reduced holdings. 39 funds opened positions while 60 raised stakes. 31.82 million shares or 0.22% more from 31.75 million shares in 2017Q3 were reported. Timessquare Mngmt Ltd Com owns 0.17% invested in Amedisys, Inc. (NASDAQ:AMED) for 481,695 shares. Federated Investors Incorporated Pa reported 1,910 shares. Laurion Management Lp holds 0% or 7,907 shares. 47,331 were reported by Prudential. Virginia Retirement Et Al accumulated 20,100 shares. Pinebridge L P invested in 46,675 shares or 0.06% of the stock. Ubs Asset Americas Incorporated has invested 0% in Amedisys, Inc. (NASDAQ:AMED). Dimensional Fund Advisors Ltd Partnership owns 1.17 million shares. Hbk Limited Partnership, Texas-based fund reported 48,300 shares. Tygh Cap Mgmt, Oregon-based fund reported 114,965 shares. Rhumbline Advisers invested in 0.01% or 65,009 shares. Deutsche National Bank & Trust Ag, a Germany-based fund reported 79,645 shares. Trexquant Invest Ltd Partnership invested 0.1% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). Bnp Paribas Arbitrage holds 12,254 shares. Clarivest Asset Mngmt Lc owns 76,880 shares.

Amedisys, Inc. (NASDAQ:AMED) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts